NCT05223738 is a clinical trial in Vitiligo, sponsored by Kasr El Aini Hospital.

Who is sponsoring NCT05223738?

NCT05223738 is sponsored by Kasr El Aini Hospital.

Is NCT05223738 still recruiting?

NCT05223738 is currently status unknown. Last updated 4 February 2022.

Last reviewed 2022-02-04 · How we verify

NCT05223738

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Resident Memory T Cells in Vitiligo

Status unknown Last updated 4 February 2022

What this trial tests

trial in Vitiligo in 29 participants. Status unknown.

Timeline

31 December 2020

Primary endpoint
30 March 2021

1 February 2022

Quick facts

Lead sponsor	Kasr El Aini Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	29
Start date	31 December 2020
Primary completion	30 March 2021
Estimated completion	1 February 2022
Sites	1 location across Egypt

Conditions studied

Vitiligo — all drugs for Vitiligo →

Sponsor

Kasr El Aini Hospital

Who can join

Adults 18 to 60, any sex, with Vitiligo. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to detect the presence and diversity of Tissue resident memory T cell populations in early and late cases of generalized non-segmental Vitiligo.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tissue-resident memory T cells in diseases and therapeutic strategies.
Xie D, Lu G, Mai G, Guo Q, et al · · 2025 · cited 5× · PMID 39802636 · DOI 10.1002/mco2.70053

Verify or expand the search:

Other recruiting trials for Vitiligo

Currently open trials in the same condition.

NCT07153666 — A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo · recruiting
NCT07267273 — Betamethasone Phonophoresis For Vitiligo · NA · recruiting
NCT07232238 — TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients · active not recruiting
NCT07532330 — Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo · NA · active not recruiting
NCT07357870 — A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo · Phase 1 · recruiting

Other Kasr El Aini Hospital trials

Trials by the same sponsor.

NCT07438652 — Effect of Mediterranean vs Paleolithic Diet on RA Activity, Sarcopenia and QOL: 12-Week RCT · NA · recruiting
NCT07488039 — Labroplasty in Cases of Anterior Shoulder Instability With Subcritical Glenoid Bone Loss · NA · recruiting
NCT07274280 — Comparative Evaluation of Ambu AuraGain, LarySeal Pro and I-gel in Pediatric Airway Management for Day-Case Surgery Unde · NA · not yet recruiting
NCT07348146 — Hand-Sewn vs. Stapled Anastomosis in SADI-S: Early Postoperative Complications. · NA · enrolling by invitation
NCT07077265 — Comparing Two Different Norepinephrine Infusion Rates for Prophylaxis Against Spinal-induced Hypotension in Elderly · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05223738 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kasr El Aini Hospital
Last refreshed: 4 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05223738.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing